

OXIDIEN PHARMACEUTICALS TO PRESENT AT THE 2020 BIO CEO & INVESTOR CONFERENCE

GAINESVILLE, FL, US, February 6, 2020 /EINPresswire.com/ -- Oxidien Pharmaceuticals, a clinical-stage biopharmaceutical company developing a best-in-class enzyme therapeutic for an underserved kidney disease indication, today announced that it will present a corporate overview at the BIO CEO & Investor Conference, being held at the Marriott Marquis Times Square in New York City.

Presentation Details:

Date: Monday, February 10th, 2020

Time: 3:45 p.m. (ET) Location: Wilder Room

ABOUT OXIDIEN PHARMACEUTICALS, LLC

Oxidien Pharmaceuticals is a clinical stage biopharmaceutical company addressing a large unmet need in kidney disease. The company is focused on treating secondary hyperoxaluria using novel oral enzymatic approaches. Oxidien has a strong intellectual property position with patents pending world-wide. The leadership team has a proven track record of successful product development, regulatory approval, and with operating, growing and exiting healthcare businesses. Oxidien Pharmaceuticals is located in UF Innovate the Hub - a world-recognized leader in biotechnology business incubation affiliated with one of the nation's leading research institutions, the University of Florida. For additional information on UF Innovate the Hub please visit http://innovate.research.ufl.edu/. For additional information on Oxidien please visit http://innovate.research.ufl.edu/. For additional information on Oxidien please visit http://innovate.research.ufl.edu/. For additional information on Oxidien please visit

Helena Cowley
Oxidien Pharmaceuticals
+1 352-672-5320
email us here
Visit us on social media:
Twitter
LinkedIn

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2020 IPD Group, Inc. All Right Reserved.